Department of Public Health, University of Copenhagen, Copenhagen, Denmark.
CPO Piemonte, AOU San Giovanni Battista, Torino, Italy.
Eur J Cancer. 2014 Jan;50(1):185-92. doi: 10.1016/j.ejca.2013.08.013. Epub 2013 Sep 13.
There is concern about detection of ductal carcinoma in situ (DCIS) in screening mammography. DCIS accounts for a substantial proportion of screen-detected lesions but its effect on breast cancer mortality is debated. The International Cancer Screening Network conducted a comparative analysis to determine variation in DCIS detection.
Data were collected during 2004-2008 on number of screening examinations, detected breast cancers, DCIS cases and Globocan 2008 breast cancer incidence rates derived from national or regional cancer registers. We calculated screen-detection rates for breast cancers and DCIS.
Data were obtained from 15 screening settings in 12 countries; 7,176,050 screening examinations; 29,605 breast cancers and 5324 DCIS cases. The ratio between highest and lowest breast cancer incidence was 2.88 (95% confidence interval (CI) 2.76-3.00); 2.97 (95% CI 2.51-3.51) for detection of breast cancer; and 3.49 (95% CI 2.70-4.51) for detection of DCIS.
Considerable international variation was found in DCIS detection. This variation could not be fully explained by variation in incidence nor in breast cancer detection rates. It suggests the potential for wide discrepancies in management of DCIS resulting in overtreatment of indolent DCIS or undertreatment of potentially curable disease. Comprehensive cancer registration is needed to monitor DCIS detection. Efforts to understand discrepancies and standardise management may improve care.
在筛查性乳房 X 光检查中,人们对导管原位癌(DCIS)的检测存在担忧。DCIS 占筛查出的病变的很大一部分,但它对乳腺癌死亡率的影响仍存在争议。国际癌症筛查网络进行了一项比较分析,以确定 DCIS 检测的差异。
2004 年至 2008 年期间,我们收集了筛查检查次数、检出的乳腺癌、DCIS 病例以及来自国家或地区癌症登记处的 2008 年全球癌症发病率数据。我们计算了乳腺癌和 DCIS 的筛查检出率。
我们从 12 个国家的 15 个筛查机构获得了数据,涵盖了 7176050 次筛查检查、29605 例乳腺癌和 5324 例 DCIS 病例。乳腺癌发病率最高和最低的比值为 2.88(95%置信区间 2.76-3.00);乳腺癌检出率为 2.97(95%置信区间 2.51-3.51);DCIS 检出率为 3.49(95%置信区间 2.70-4.51)。
我们发现 DCIS 的检测存在相当大的国际差异。这种差异不能完全用发病率或乳腺癌检出率的差异来解释。这表明,在 DCIS 的管理上可能存在广泛的差异,导致对惰性 DCIS 的过度治疗或对可能可治愈的疾病的治疗不足。全面的癌症登记是监测 DCIS 检测的必要手段。努力了解差异并标准化管理可能会改善护理。